Advertisement

Chemotherapeutic Management of Bladder Cancer

  • Donald J. Higby
Part of the Developments in Oncology book series (DION, volume 2)

Abstract

Transitional cell carcinoma of the urinary bladder is one of the leading causes of cancer death in the United States. The disease is seen most commonly in older age groups and shows a preponderance for males (1). Carcinoma of the bladder is almost certainly produced in the majority of cases by exposure to carcinogenic substances, as evidenced by the higher frequency noted in patients with urinary tract obstruction and the increased incidence in aniline dye workers and smokers (2–4).

Keywords

Bladder Cancer Transitional Cell Carcinoma Urinary Tract Obstruction Report Response Rate Advanced Bladder Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Silverberg, E, A Halleb, Cancer statistics - 1972. Cancer 22:2, 1972Google Scholar
  2. 2.
    Cole, P, RR Manson, H Haring, et al, Smoking and cancer of the lower urinary tract. New Engl J Med 284:129, 1971PubMedCrossRefGoogle Scholar
  3. 3.
    Cole, P, R Hoover, GH Friedell, Occupational cancer of the lower urinary tract. Cancer 29:1250, 1972PubMedCrossRefGoogle Scholar
  4. 4.
    Hoover, R, P Cole, Temperai aspects of occupational bladder carcinogenesis. New Engl J Med 288:1040, 1973PubMedCrossRefGoogle Scholar
  5. 5.
    Murphy, GP, Chemotherapy of bladder cancer. NY State J Med 38:1889, 1977Google Scholar
  6. 6.
    del Regato, JA, HJ Spjut, Cancer: Diagnosis, Treatment, and Prognosis. 5th edition, St. Louis, Missouri, C.V. Mosby, Co., 1977, p 637–639Google Scholar
  7. 7.
    Goffinet, DR, MJ Schreider, EJ Glatstein, et al, Bladder cancer: results of radiation therapy in 384 patients. Radiol 117:149, 1975Google Scholar
  8. 8.
    Tannock, I, Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep 62:1117, 1978PubMedGoogle Scholar
  9. 9.
    Dewitt, HJ, Cancer of the bladder: diagnosis and staging. Cancer 32:1072, 1973CrossRefGoogle Scholar
  10. 10.
    Wizenberg, MJ, FG Bloedorn, JD Young, et al, Radiation therapy and surgery in the treatment of carcinoma of the bladder. Amer J Roentgenol 96:113, 1966PubMedGoogle Scholar
  11. 11.
    Wilson, W, Chemotherapy of human solid tumors with 5-fluorouracil. Cancer 13:1230, 1960PubMedCrossRefGoogle Scholar
  12. 12.
    Moore, G, ID Bross, R Ausman, et al, Effect of 5-fluorouracil in 389 patients with cancer. Cancer Chemother Rep 52:641, 1968PubMedGoogle Scholar
  13. 13.
    Glenn, J, L Hunt, J Cathem, Chemotherapy of bladder carcinoma with 5fluorouracil. Cancer Chemother Rep 27:67, 1963PubMedGoogle Scholar
  14. 14.
    Ansfield, F, J Schroeder, A Carreri, Five years clinical experience with 5fluorouracil. JAMA 181:295, 1962PubMedGoogle Scholar
  15. 15.
    Field, J, Fluorouracil treatment of advanced cancer in ambulatory patients. Cancer Chemother Rep 24:99, 1962Google Scholar
  16. 16.
    Weiss, A, L Jackson, R Carabasi, An evaluation of 5-f luorouracil in malignant disease. Ann Intern Med 55:731, 1961PubMedGoogle Scholar
  17. 17.
    Prout, GR, ID Bross, NH Slack, et al, Carcinoma of the bladder: 5fluorouracil and the critical role of a placebo. Cancer 22:926, 1968PubMedCrossRefGoogle Scholar
  18. 18.
    Pavone-Macaluso, M, Chemotherapy of vesical and prostatic tumors. Brit J Urol 43:701, 1971PubMedCrossRefGoogle Scholar
  19. 19.
    Fox, M, The effect of cyclophosphamide on some urinary tract tumors. Brit J Urol 37:399, 1965PubMedCrossRefGoogle Scholar
  20. 20.
    Wall, RL, KP Clausen, Carcinoma of the urinary bladder in patients receiving cyclophosphamide. New Engl J Med 293:271, 1975PubMedCrossRefGoogle Scholar
  21. 21.
    Bonadonna, G, Phase I and preliminary Phase II evaluation of adriamycin. Cancer Res 30:2752, 1970Google Scholar
  22. 22.
    Tan, C, E Etcubanas, N Wollner, et al, Adriamycin-an antitumor antibiotic in the treatment of neoplastic diseases. Cancer 32:9, 1973PubMedCrossRefGoogle Scholar
  23. 23.
    Middleman, E, J Luce, E Frei, Clinical trials with adriamycin. Cancer 28:844, 1971PubMedCrossRefGoogle Scholar
  24. 24.
    O’Bryan, RM, Phase II evaluation of adriamycin in human neoplasia. Cancer 32:1, 1973PubMedCrossRefGoogle Scholar
  25. 25.
    Weinstein, SH, JD Schmidt, Doxorubicin chemotherapy in advanced transitional cell carcinoma. Urology 8:336, 1976PubMedCrossRefGoogle Scholar
  26. 26.
    Rosenberg, B, L Van Camp, JE Trosko, et al, Platinum compounds: a new class of potent antitumor agents. Nature 222:385, 1969PubMedCrossRefGoogle Scholar
  27. 27.
    Sirica, A, JM Venditti, I Kline, Enhanced survival response of L-1210 leukemic mice to a single combination treatment with cis-platinum (II) diammine dichloride plus cyclophosphamide. Proc Amer Assoc Cancer Res 12:4, 1971Google Scholar
  28. 28.
    Speer, RJ, S Lapis, H Ridgeway, et al, Cis-platinum diamminodichloride in combination therapy of leukemia L-1210. Wadley Med Bull 1:103, 1971Google Scholar
  29. 29.
    Higby, DJ, HJ Wallace, Jr, D Albert, JF Holland, A phase I study showing responses in testicular and other tumors. Cancer 33:1219, 1974PubMedCrossRefGoogle Scholar
  30. 30.
    Wiltshaw, E, T Kroner, Phase II study of cis-dichlorodiammineplatinum in advanced adenocarcinoma of the ovary. Cancer Treat Rep 60:55, 1976PubMedGoogle Scholar
  31. 31.
    Bruckner, HW, CJ Cohen, B Kabakow, et al, Combination chemotherapy of ovarian carcinoma with platinum: improved therapeutic index. Proc Amer Assoc Cancer Res 18:339, 1977Google Scholar
  32. 32.
    Ostrow, S, D Hahn, P Wiernik, et al, Ophthalmologic toxicity after cisdichlorodiammine-platinum therapy. Cancer Treat Rep 62:1591, 1978PubMedGoogle Scholar
  33. 33.
    Kahn, A, JM Hill, W Grater, et al, Atopic hypersensitivity to cisdichlorodiammineplatinum and other platinum complexes. Cancer Res 35:2766, 1975Google Scholar
  34. 34.
    Yagoda, A, R Watson, IC Gonzalez-Vitale, Cis-dichlorodiammineplatinum in advanced bladder cancer. Cancer Treat Rep 60:917, 1976PubMedGoogle Scholar
  35. 35.
    Hayes, D, E Cvitkovic, R Goldberg, et al, Amelioration of renal toxicity of high dose cis-platinum diammine dichloride by mannitol induced diuresis. Proc Amer Assoc Cancer Res 17:109, 1976Google Scholar
  36. 36.
    Merrin, C, A new method to prevent toxicity with high doses of cis-diammine platinum. Proc Amer Assoc Cancer Res 17:243, 1976Google Scholar
  37. 37.
    Early, K, EG Elias, A Mittelman, et al, Mitomycin C in the treatment of metastatic transitional cell carcinoma of the urinary bladder. Cancer 31:1150, 1973PubMedCrossRefGoogle Scholar
  38. 38.
    Altman, CC, NJ McCague, AC Ripepi, The use of methotrexate in advanced carcinoma of the bladder. J Urol 108:271, 1972PubMedGoogle Scholar
  39. 39.
    Howe, C, M Samuels, Phase II studies of hydroxyurea in adults: urologic and gynecologic neoplasms. Cancer Chemother Rep 40:47, 1964PubMedGoogle Scholar
  40. 40.
    Cross, RJ, GP Yorkshire, Treatment of advanced bladder cancer with adriamycin and fluorouracil. Brit J Urol 48:605, 1976CrossRefGoogle Scholar
  41. 41.
    Williams, SD, RJ Rohn, JP Donahue, et al, Chemotherapy of bladder cancer with cis-diammine dichloroplatinum, adriamycin, and 5-f luorouracil. Proc Amer Assoc Cancer Res 19:316, 1978Google Scholar
  42. 42.
    Yagoda, A, R Watson, N Kemeny, et al, Diammine dichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancer. Cancer 41:2121, 1978PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers bv, The Hague 1980

Authors and Affiliations

  • Donald J. Higby
    • 1
  1. 1.Roswell Park Memorial InstituteBuffaloUSA

Personalised recommendations